Featured

Hundreds of Studies Show DMSO Transforms the Treatment of Cancer

Cancer is one of the most challenging conditions to deal with in medicine, as two seemingly identical cancers can have very different causes. As a result, any standardized (holistic or conventional) protocol will inevitably fail some of the patients it is meant to treat.

Furthermore, since there is so much fear surrounding cancer (e.g., from what the primal fear brings up inside you, from how your social circle reacts to it and from how the medical system uses all of that to push cancer therapies) it is often very difficult to have a clear head about the ordeal or find the right source of advice.

Likewise, since so much money is involved (e.g. 65% of oncologist’s revenues comes from chemotherapy drugs and cancer drugs are by far the most profitable drug market), there is significant pushback (e.g. from medical boards or unhappy relatives) against anyone who attempts alternative cancer therapies making it very difficult to practice unconventional cancer care—particularly since no alternative treatment works all the time.
Note: in a recent article, I highlighted how urologists initially would not touch Lupron (which is now also used as a the puberty blocker) because of how unsafe and ineffective it was, but once they started being paid a lot of money to prescribe it for prostate cancer, it rapidly became their number one drug.

In contrast, while the conventional cancer therapies often have serious issues that make them far worse than any benefit they offer, some conventional cancer therapies are frequently the only available option which can save someone’s life (which has led to me at different times having fights with close friends or relatives either not to do chemotherapy or to get them to start it in cases where I felt it was absolutely necessary).

Given all of this, I presently believe that no “ideal” cancer treatment exists, but if it can be done (e.g., it’s effective for the cancer and feasible to implement), the most ideal to least ideal treatments are as follows:

•Identifying the root cause of a cancer, removing it, and having it quickly and permanently go away on its own (which is sometimes possible).

•Have enough time to rebalance the body so that its terrain no longer supports the cancer and the cancer can fade away on its own (which is often doable but a fairly involved process many have difficulty carrying out).

•Significantly enhance the function of the immune system so that it will eliminate the cancer.

•Find a treatment that is toxic to the cancer but relatively benign to the rest of the body.

•Find a treatment with an acceptable toxicity level and find ways to mitigate its side effects.

•Accept a moderately toxic treatment with significant side effects.

•Focus on living with the cancer rather than curing it and then finding ways to mitigate the symptoms you experience both from it and any existing treatment protocols.

•Use a costly conventional therapy that is unlikely to work and live with all the side effects until your life ends (which in more extreme treatment regimens can be quite severe).

If we take a step back, what’s truly remarkable about DMSO, depending on how it is used, is that it can effectively provide most of the benefits listed above with the least amount of collateral damage (e.g., side-effects, toxicity, etc.).

Dimethyl Sulfoxide (DMSO)

Exactly six months ago, I used this newsletter to bring the public’s attention to DMSO, a simple naturally occurring compound that has a number of immense therapeutic benefits and virtually no toxicity (detailed here). In turn, when it was discovered in the 1960s, it quickly became America’s most desired drug (as it cured many incurable ailments). A lot of the scientific community promptly got behind it and before long, thousands of papers had been published on every conceivable medical application for it.

As such, throughout this series, I’ve presented the wealth of evidence that DMSO effectively treats:

Strokes, paralysis, a wide range of neurological disorders (e.g., Down Syndrome and dementia), and many circulatory disorders (e.g., Raynaud’s, varicose veins, hemorrhoids), which I discussed here.

A wide range of tissue injuries, such as sprains, concussions, burns, surgical incisions, and spinal cord injuries (discussed here).

Chronic pain (e.g., from a bad disc, bursitis, arthritis, or complex regional pain syndrome), which I discussed here.

A wide range of autoimmune, protein, and contractile disorders such as scleroderma, amyloidosis, and interstitial cystitis (discussed here).

A variety of head conditions, such as tinnitus, vision loss, dental problems, and sinusitis (discussed here).

A wide range of internal organ diseases such as pancreatitis, infertility, liver cirrhosis, and endometriosis (discussed here).

A wide range of skin conditions such as burns, varicose veins, acne, hair loss, ulcers, skin cancer, and many autoimmune dermatologic diseases (discussed here).

Many challenging infectious conditions, including chronic bacterial infections, herpes, and shingles (discussed here).

In turn, when I published this series (because of both how effective and easily accessible DMSO is) it caught on like wildfire, this publication went from being the ninth to top ranked newsletter in the genre, there was a nationwide DMSO shortage, and I’ve received almost two thousand testimonials from people who benefitted from DMSO (and often had remarkable results—particularly for chronic pain).

That response was quite surprising and in my eyes, a testament not only to how well DMSO works, but more importantly, how effectively DMSO’s story was erased from history (e.g., many long-time enthusiasts of natural health shared that they were blown away they’d never heard of it). This sadly illustrates how effectively the medical industry can bury anything threatening its bottom line (e.g., the FDA—for rather petty reasons—used everything at their disposal to make sure DMSO was forgotten).

In turn, within the DMSO story, I believe one of the least appreciated (or even known) facets of it are the remarkable contributions DMSO makes to the treatment of cancer—which is even more remarkable given that far more research has been done with DMSO and cancer than all the other topics I just listed. Consequently, for months I’ve wanted to publish an article on this (particularly since one incredible natural cancer therapy utilizes DMSO), but simultaneously, it just wasn’t feasible to as there was so much literature to go through.

That’s been weighing on me considerably (e.g. many readers have asked me to prioritize this article over everything else), so over the last three months (and particularly the last three weeks), I shifted my responsibilities to focus on the topic thoroughly. While it took a bit of a toll on me, the article is now done. As such, I greatly hope some of what’s in here can benefit you and I likewise thank each of you who has supported this newsletter and made it possible for me to spend so much time delving into these critical forgotten sides of medicine.

Cancer Differentiation

When life begins, the first cell has the potential to turn into anything. Then as it divides, its range of possibilities becomes more finite until each needed type of cell populates its assigned region of the body. This process is known as differentiation, and is a frequent interest in medicine as undifferentiated cells (e.g., stem cells) can replace lost cells by differentiating into them. Cancer is a disease of dedifferentiation where normal cells adopt an ancient survival program, lose their structure, order, and connection to the whole body, and instead voraciously divide through the body and consume it.

As such, an agent that could induce differentiation of cancer cells so they become normal could be immensely helpful in treating cancer. Unfortunately, only one “effective” agent has entered general medical practice, all-trans retinoic acid (a metabolite of vitamin A) for the treatment of promyelocytic leukemia (a relatively rare cancer).

There are now twelve tumor-cell types in the test tube in which DMSO tends to stimulate the tumor cell toward changing into a more normal cell, Dr. Jacob told me. — Morton Walker 1983

Sadly, to quote a 2023 review paper that compiled many studies where DMSO differentiated cancers:

Recently, DMSO has been included in biological cancer treatment and several FDA approved cancer immune therapeutic modalities such as CarT cell therapy and melanoma drug Mekinist (trametinib DMSO). However, besides its recognized biological role as a pharmaceutical solvent and cryoprotectant, there was no mention of DMSO’s possible ability to potentiate therapeutic activity as a component of these cancer treatments.

Note: while there is a general bias in medicine to avoid researching natural cancer therapies, DMSO has been extensively used in cancer research because it effectively facilitates many aspects of it (which had led to the truly curious scenario described above).

This saga began in 1971 when one of the nations top virologists accidentally discovered that if DMSO was given to leukemic cells (specifically erythroblasts—which cause a relatively rare type of cancer), at a 2% concentration, it caused most of them to differentiate back to normal cells (which took up to 5 days), at 3% it stopped their growth, and at 5% it killed them.

Additionally:

•Mice injected with the DMSO-treated cancer cells lived roughly twice as long as those injected with untreated cancer cells (suggesting DMSO made the cancer less aggressive).

•The cancer cells did not evolve resistance to DMSO (although subsequent research sometimes showed a small portion of cancer cells in a tumor were resistant to DMSO1,2). Additionally, for erythroleukemic cells that were resistant to DMSO inducing differentiation, butyrate did induce it (while butyrate and DMSO each antagonize the inducing action of the other).

Eight months later, she published another study that found that within five days, 2% DMSO caused 95% of erythroleukemic cells to differentiate. This was followed by studies that:
•Explored the mechanisms of differentiationprovided detailed descriptions of it, and showed it occurred in a consistent manner.
Explored how certain steroids blocked (or supported) DMSO’s ability to induce erythroleukemic differentiation.
Found increasing concentrations of DMSO caused increasing alterations of cancer DNA (which was an initial step in the differentiation process).
• Found the differentiation continued long after DMSO was no longer present and could be irreversible.
•Found the differentiation did not appear to be synchronized with the cell cycle.1,2

Following this, it became generally accepted that DMSO differentiates erythroleukemic cells, and decades of studies corroborated that.123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960, 6162

Note: DMSO’s ability to differentiate erythroleukemic cells was so well recognized that in 1992, it was selected for a microgravity experiment on the international space station.

Since erythroleukemia is closely related to the more common acute lymphoblastic leukemia (AML), decades of studies also showed DMSO differentiated AML.1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556575859606162636465666768697071727374757677787980818283848586878889909192939495

Additionally, DMSO was also shown to differentiate many other cancers.

Blood Cancers: acute promyelocytic leukemia,1,2 chronic myeloid leukemia,1,2,3 cutaneous erythromyeloleukemia,1 hairy cell leukemia,1 histiocytic lymphoma,1,2,3 non-Hodgkin lymphoma,1 T-cell leukemia,1 T-cell lymphoma1

Organ Cancers: bladder1, brain,1,2,3,4,5,6 breast,1 colon,1 esophageal,1,2 intestinal1,2 kidney,1,2 liver,1,2,3,4,5,6,7,8 lung,1,2,3,4 prostate,1,2 rectal,1 ovarian,1,2 stomach1, thyroid1

Other Cancers: embryonic carcinoma (into heart cells),1,2,3,4,5,6 fibrosarcoma,1,2 melanoma,1,2,3,4,5,6,7,8,9,10,11, nasopharyngeal,1 rhabdomyosarcomas1,2 tumors (in potatoes)1

Collectively, these studies showed:

•DMSO normally differentiated the cancer (it was rare for me to find studies where it did not) and did so in a dose-dependent fashion (e.g., 0.5-2% was often used). At higher concentrations (e.g. 1.5%), those changes were often permanent. However, in some cases, a minority of DMSO resistant cells did form, which then required another differentiating agent.

•Cancer growth, proliferation, and survival in tandem frequently decreased. In parallel, tumor suppressing genes (e.g., P21PTENRB) increased, tumor promoting proteins were suppressed, and the cancer cells were weakened (e.g., with transient DNA strand breaks1,2) or induced into programmed cell death. Conversely, cancer triggers (e.g., C-myc1,2,3C-mybnucleolar antigen p145) were suppressed.

•Many metabolic pathways (e.g., JAK–STATERKNF-kB), histone H2A phosphorylation, and key cellular enzymes were increased during differentiation (e.g., Protein Kinase C,1,2,3 PI 3-kinaseTXA2, and TXB2 synthase, COX-21,25-LipoxygenasephospholipaseCYP3A4cytochrome b5 reductase and drug metabolismacetylcholinesterase, carbonic anhydrase,1,2 disphosphase, and diaphorase).

•Other proteins and receptors were also increased (e.g., GPI-80angiotensin IIDesmoplakins and Fibronectin) as were a variety of metabolites and signaling molecules (TNF-αmelanindiacylglycerol inositol). Intercellular calcium was also increased1,2,3 as was the ion flux in and out of cells (except for potassium), the cellular transport of nucleosides. Finally, there were changes in G-protein signaling, and some cells were sensitive to staphylococcal leukocidin.

•Certain aspects of metabolism decreased (e.g., glucose transportinsulin receptor availabilitygeneral protein and transferrin synthesisdiacylglycerol synthesis, glycosaminoglycan synthesis and sulfate incorporation, heme oxygenase-1 activity,1,2) along with a decrease in histone expression and the association of Phosphatidylinositol-Transfer protein with the nucleus.

•Some things increased DMSO’s differentiation (e.g., TNF-α1,2,3sphinganinealpha-lipoic-acidPP2, or suppressing PTEN) while others suppressed it (e.g., asbestos1,2dexamethasone,1,2 hydrocortisonehyperthermiadiacylglycerols and phospholipase Cblocking protein kinase C, lithium chlorideMu IFN-Alpha1). Additionally, low frequency EMFs did not affect it.
Note: other agents also exist that can sometimes induce cell differentiation, but in many cases, DMSO works much better (e.g., oxytocin can turn certain cells into heart cells, but does not fully differentiate them if they are initially only one layer, whereas DMSO does).

•Vitamin D has been repeatedly found to synergistically enhance DMSO’s ability to differentiate AML1,2,3,4 (except in this study) and to commit AML to differentiate into macrophages1,2 while it counteracted DMSO differentiating erythroleukemia.1,2

•Retinoic acid (a vitamin A metabolite) has also shown promise for inducing cancer differentiation, works synergistically with DMSO1,2 and uses a different differentiating pathway than DMSO.1,2

In addition to these biochemical changes, some other effects of DMSO have been proposed to explain its differentiating activity (e.g., one study proposed that DMSO’s interactions with free radicals allowed it to induce differentiation).

Note: I have strong ethical objections to animal research and it is my sincere hope that since so much of it has already been done that it will not need to be redone to “prove” DMSO works.

Read the Whole Article

Source link

Related Posts

1 of 42